MedTrace Logo

A Study to Evaluate the Mass Balance of [14C] HRS-5965 in Healthy Adult Male Volunteers

NCT06567392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-10-15

No results posted yet for this study

Summary

Evaluate the Mass Balance of \[14C\] HRS-5965 in Healthy Adult Volunteers.

Conditions

  • Complement Mediated Primary or Secondary Glomerular Diseases

Interventions

DRUG

[14C] HRS-5965

Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.

Sponsors & Collaborators

  • Chengdu Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-03
Primary Completion
2024-10-08
Completion
2024-10-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06567392 on ClinicalTrials.gov